AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04049266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSI-301
Description: Intravitreal Injection
Study NCT04049266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Intravitreal Injection
Study NCT04049266 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
Study NCT04049266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
Study NCT02579044 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Everolimus and lonafarnib
Study NCT02671435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Participants will receive IV infusion of cetuximab as stated in arm description.
Study NCT02093845 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biomatrix NeoFlex coronary stent
Description: Percutaneous coronary intervention involving use of stent
Study NCT02093845 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SYNERGY stent
Description: Percutaneous coronary intervention involving use of stent
Study NCT03944954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo TMS Sham
Description: Individuals will receive placebo dose and sham TMS.
Study NCT03944954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marinol 10Mg Capsule TMS Sham
Description: Individuals will receive 10mg dose and sham TMS.
Study NCT03215992 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Diffuse Optical Tomography (DOT) System
Description: Diffuse optical tomography (DOT) is a novel imaging modality that uses low-intensity, near-infrared light to characterize tissue. As light of a specific wavelength travels through tissue, it is absorbed and scattered by different chromophores and cellular structures. Using four wavelengths of light allows the detection of four chromophores: oxyhemoglobin, deoxyhemoglobin, water and fat.
Study NCT03944954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marinol 30Mg Capsule TMS Sham
Description: Individuals will receive 30mg dose and sham TMS.
Study NCT03944954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo TMS Real
Description: Individuals will receive placebo and real TMS.
Study NCT02671435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Participants will receive IV infusion of mFOLFOX as stated in arm description.
Study NCT02671435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Participants will receive IV infusion of bevacizumab as stated in arm description.
Study NCT03252886 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal Intubation
Description: Insertion of endotracheal tube into the trachea and supply oxygen using the Ambu-bagging during cardiopulmonary resuscitation
Study NCT03433833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin oral route once daily for 24 weeks.
Study NCT03240367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coutery
Description: Stapler line bleeding control with coutery
Study NCT02309645 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EVICEL® Fibrin Sealant
Description: Subjects randomized to receive EVICEL® Fibrin Sealant (Human), a thin layer will be applied to the entire length of the suture line and the adjacent area to at least 5mm away, including all suture holes.
Study NCT02309645 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sutures Only
Description: Subjects randomized to Control (Additional Sutures) will receive additional dural repair sutures applied immediately to the dural suture line after randomization as deemed necessary by the surgeon.
Study NCT00555763 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tonometry
Description: Tonometry : measurement of intraocular pressure with an applanation tonometer
Study NCT03092830 — intervention group
Intervention type: GENETIC
Intervention: Molecular testing of DNA/RNA from skin tumors, SCC/BCC
Description: Molecular testing of DNA/RNA from skin tumors, SCC/BCC
Study NCT03006848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Patients will be administered avelumab at a dose of 10 mg/kg intravenously (IV) over 60 minutes on days 1 and 15 of each cycle, with a cycle lasting 28 days. Patients will receive avelumab every 2 weeks in cycles of 28 days for up to 24 months, or 26 cycles.
Study NCT03006848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: To assess quality of life, patients will complete questionnaires at four time points.
Study NCT05559840 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: S-Condom Uterine Tamponade
Description: The condom catheter will be inflated with air
Study NCT05559840 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Traditional condom catheter
Description: The condom catheter will be inflated with saline following national protocol
Study NCT03484507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: 1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit
Study NCT03484507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: 1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit
Study NCT03484507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: 1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit
Study NCT03484507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone Sodium Phosphate
Description: 1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11
Study NCT03484507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxypropyl Methylcellulose
Description: 1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11
Study NCT03484507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone Sodium Phosphate
Description: 1 drop 4 times daily for weeks 6-9, then 2 times daily for weeks 10-11
Study NCT03484507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxypropyl Methylcellulose
Description: 1 drop 4 times daily for weeks 4-5
Study NCT03267043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention (FNI)
Description: Subjects will be guided by the nursing staff through an enhanced program of mother/infant interactions, which include skin-to-skin holding.
Study NCT03267043 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Established routine care provided on the NICU floor by specially trained health care professionals.
Study NCT04210362 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workshops on responsive caregiving
Description: Caregivers will receive monthly workshops about several dimensions of nurturing care, responsive caregiving and early child development. Workshops will be reinforced through home visits.
Study NCT03879434 — intervention group
Intervention type: DEVICE
Intervention: Ostenil® Mini
Description: Ostenil® Mini is a CE-certified viscoelastic solution for injection into the Joint cavity, containing 1.0 % sodium hyaluronate from fermentation
Study NCT03944954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Marinol 10Mg Capsule TMS Real
Description: Individuals will receive10mg THC and real TMS. Intervention type: Other (combination device/drug intervention)
Study NCT03944954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Marinol 30Mg Capsule TMS Real
Description: Individuals will receive 30mg THC and real TMS. Intervention type: Other (combination device/drug intervention)
Study NCT03557463 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dairy protein
Description: A controlled, randomized, double blind pilot study was conducted using two different protein sources as nutritional supplementation to enhance vaccine response.
Study NCT03557463 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dairy protein
Description: A controlled, randomized, double blind pilot study was conducted using two different protein sources as nutritional supplementation to enhance vaccine response.
Study NCT00594984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: IV solution, IV, QW, 400 mg/m2 X 1, followed by 250mg/m2, until progression
Study NCT00594984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cetuximab
Description: IV solution, IV, QW, 400 mg/m2 X 1, followed by 250mg/m2, until progression
Study NCT00594984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: IV solution, IV, Q3W, 350 mg/m2, until progression
Study NCT00594984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Irinotecan
Description: IV solution, IV, Q3W, 350 mg/m2, until progression
Study NCT00594984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brivanib
Description: Oral, Tablet, QD, (200 mg, 400 mg, 600 mg, 800 mg dose escalation) until progression
Study NCT00594984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Brivanib
Description: Oral, Tablet, QD, MTD determined in Arm 1, Phase 1, until progression
Study NCT00594984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brivanib Placebo
Description: Oral, tablet, QD, until progression
Study NCT00594984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Brivanib Placebo
Description: Oral, tablet, QD, until progression
Study NCT03223246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional teaching
Description: A brief safety intervention, combining a pictorial handout, dosing demonstration with dispensed syringe, and teach-back for confirmation of understanding.
Study NCT03077750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VBP-245 Topical Gel
Description: Topical application BID
Study NCT03077750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Control With No Active Pharmaceutical Ingredients
Study NCT02104713 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic (MSC's) Application to the Burn Wounds
Description: Allogeneic (MSC's) Application to the Burn Wounds. The first group of 5 will be started on the lowest dose. If there are no adverse reactions, the second group of 5 will receive a higher dose. This will be repeated for the third and fourth groups with each receiving a higher dose~1. Initial dose level will be 2.5 x 10³ Allogeneic MSCs cells/square cm.~2. Second dose level 5 X 10³ Allogeneic MSCs cells/square cm.~3. Third dose level 1 X 10⁴ Allogeneic MSCs cells/square cm.~4. Fourth dose level 2 X 10⁴ Allogeneic MSCs cells/square cm.~Up to 2 administrations of cells will be allowed per dose level to be given over a period of no more than 8 weeks. Each administration of cells will be no less than ten days apart and no more than 6 weeks apart.
Study NCT01935271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Muscle Armor Supplement
Study NCT01935271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01965496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX168
Description: A injection administered subcutaneously
Study NCT03551054 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy for Two, Healthy for You
Description: Remotely delivered health coaching in pregnancy and postpartum to promote healthy weight gain.
Study NCT03551054 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Study NCT01733602 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Study NCT01733602 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Study NCT03932721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab 140 MG/ML
Description: Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that targets LDL receptors for degradation and thereby reduces the liver's ability to remove LDL-C.
Study NCT00248989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone
Description: 3.0 ml of 0.3% DHEA cream applied on the skin twice daily.
Study NCT00248989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: 3.0 ml of placebo cream applied on the skin twice daily.
Study NCT02603419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Anti-PD-L1 antibody at X1 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression.
Study NCT02603419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Anti-PD-L1 antibody at X2 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression.
Study NCT02603419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Anti-PD-L1 antibody at X3 mg IV every 3 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression
Study NCT02603419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Anti-PD-L1 antibody at X3 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression
Study NCT02603419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Anti-PD-L1 antibody at X mg IV every 2 weeks. Treatment with avelumab will continue until disease progression
Study NCT02603419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Anti-PD-L1 antibody at X1 mg IV every 2 weeks which can be escalated to X4 mg every 2 weeks based on safety and efficacy. Treatment with avelumab will continue until disease progression.
Study NCT02049957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Sapnisertib capsules
Study NCT02049957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant IM injection.
Study NCT02049957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane tablets.
Study NCT04187651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: platelet rich plasma prepared from the patients' own blood will be applied to the fistula tract
Study NCT04101825 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auralya
Description: Hyaluronic Acid-Dermal Filler
Study NCT02236195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mocetinostat
Study NCT02468544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text messaging
Description: Text messaging mHealth intervention to improve HIV Primary Care Engagement among clients of methadone maintenance treatment programs who are living with HIV.
Study NCT03283228 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cd11b and Cd56 markers
Description: The expression of CD11b and CD56 in newly diadnosed cases of AML
Study NCT04334161 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Administration of glucose and controlled induction of hypoglycaemia.
Description: Functional metabolic test involving a 15g oral glucose load (enriched with 1.5% U-13C glucose) and subsequent controlled 20min hypoglycaemic clamp period. Neuroendocrine response will be assessed using frequent blood samples for hormones and metabolites, continuous heart rate monitoring and evaluation for hypoglycaemic symptoms.
Study NCT03583333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMI/REL FDC
Description: 500 mg Imipenem, 500 mg Cilastatin and 250 mg Relebactam powder FDC provided in a single vial
Study NCT03583333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PIP/TAZ FDC
Description: 4000 mg Piperacillin and 500 mg Tazobactam powder FDC provided in a single vial
Study NCT03583333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Open-label 600 mg Linezolid
Study NCT03583333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Open-label 600 mg Linezolid
Study NCT03735745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: 30cc of blood will be collected.
Study NCT03735745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva collection
Description: 5cc of saliva will be collected.
Study NCT03735745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue collection
Description: Up to 10mg of tissue will be collected.
Study NCT03735745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys
Description: The Behavioral Risk Factor Surveillance System (BRFSS), Functional Assessment of Cancer Therapy - Head and Neck module (FACT-HN) the Chicago Priority Scale, Cancer Survivor Unmet Needs surveys will be administered at baseline and 3 months post-surgery.
Study NCT02382393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain Performance Test (BPT, Lumos Labs, Inc)
Description: A brief, repeatable, online battery of cognitive assessments used to measure functioning in five cognitive domains across time.
Study NCT02382393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Assessment
Description: a validated, computerized cognitive assessment tool
Study NCT02022657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Truvada
Description: Truvada is a combination pill consisting of tenofovir and emtricitabine used in PrEP
Study NCT01911767 — intervention group
Intervention type: DRUG
Intervention: Dimethyl fumarate
Description: Administered as specified in treatment arm.
Study NCT01911767 — intervention group
Intervention type: DRUG
Intervention: Peginterferon beta-1a
Description: Administered as specified in treatment arm.
Study NCT02479672 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laryngoscopy
Description: Placement of endotracheal tube. If successful intubation does not occur after the first attempt at laryngoscopy, airway equipment used in further attempts will be selected at the discretion of the attending anesthesiologist.
Study NCT02479672 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Inline Stabilization
Description: Manual immobilization of Patient's neck with intention to minimize movement from baseline position
Study NCT02479672 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VividTrac®
Study NCT01663324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS intervention 1
Description: Low frequency rTMS (Magventure Mag Pro Option) applied over left temporoparietal cortex: 3000 stimuli of 1Hz rTMS (110% motor threshold); 1 minute break after 1000 and 2000 stimuli.~Arms: single site rTMS
Study NCT00741650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information and Peer advisor
Description: Information at work place and recruitment and training of one employee as a peer advisor who help colleagues who experience musculoskeletal pain with reasons to stay active, help with adjustment in the work situation to allow individuals to stay at work.
Study NCT00741650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information, peer advisor and fast referral
Description: Information at work place and recruitment and training of one employee as a peer advisor who help colleagues who experience musculoskeletal pain with reasons to stay active, help with adjustment in the work situation to allow individuals to stay at work.~In addition, the peer advisor can refer employees who do not improve to a two day educational program that also includes a medical exam and individual counselling.~In addition,
Study NCT02018588 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tryptophan
Description: graded levels of tryptophan will be given to each subject
Study NCT01962805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex Formulation A
Study NCT01962805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex Formulation B
Study NCT04587219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gam-COVID-Vac
Description: combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization in days 1 (component I rAd26-S) and 21(component II rAd5-S)
Study NCT01837602 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cMet RNA CAR T cells